Milestone of "medical fast reading society"! Yang Sen launched the first 100% virtual clinical trial

On November 15, the leading group of the State Council for deepening the reform of the medical and health system issued the notice on further promoting the experience of deepening the reform of the medical and health system in Fujian Province and Sanming City, which released major signals The circular pointed out that by the end of December 2019, all provinces should fully implement the purchase and use policies of 25 drugs under the pilot reform of centralized purchase and use of drugs organized by the state (cypress blue instrument) Will the future of drug development lie in the "face recognition" technology for an enzyme? To speed up the development of this technology, a start-up company named X-37 recently completed a round a financing of US $14.5 million to expand the number of drug development plans The company's goal is to identify candidate drugs that can be put on the market and launch human trials in 2022 (chuangjianhui) On November 18, Redhill biopharma (Redhill) announced that its antibiotic talicia was approved by the FDA for use in the treatment of adult patients with Helicobacter pylori infection, so as to reduce the risk of gastric cancer caused by Helicobacter pylori and solve the problem of antibiotic resistance of the bacteria (arterial network) Sansheng pharmaceutical and Verseau therapeutics, Inc today announced that according to the cooperation agreement between the two sides on the research and development and commercialization of innovative monoclonal antibodies for multiple cancers, they have selected vtx-0811, a monoclonal antibody targeted at PSGL-1, as the first licensed product (American news agency) The latest analysis of the three-year data of emprise (nct03363464), a large-scale real world study, was released at the 2019 annual scientific conference of the American Heart Association held in Philadelphia recently The results showed that compared with DPP-4 inhibitors and GLP-1 receptor agonists, jardiance (empagliflozin, engeliejin) was associated with reduced hospitalization risk of heart failure There is a similar risk of nonfatal atherosclerotic cardiovascular events (Sina Medical News) Thermo Fisher Scientific Inc., a maker of diagnostic equipment, is considering buying Qiagen NV, a Dutch molecular testing company, Bloomberg reported Qiagen's share price rose 13% to 33.20 euros at 1:10 p.m on the 14th (Sina Medical News) Recently, amarin announced that the FDA's endocrine and Metabolic Drug Advisory Committee approved the results by a vote, supporting the company's vascepa (icosapent ethyl) capsule as a new therapy to reduce the risk of adverse cardiovascular events The FDA is expected to respond to the drug's new drug supplement application on December 28 this year (yaomingkant) Recently, youshibi, a pharmaceutical company based in Brussels, Belgium, announced that bimekizumab, an IL-17A / F monoclonal antibody under development for the treatment of chronic moderate to severe plaque psoriasis, had reached two common primary endpoints and all secondary endpoints in the key phase 3 trials It is expected that in mid-2020, youshibi will submit regulatory applications for bimekizumab (yaomingkant) A few days ago, Johnson & Johnson Group's Yang Sen company announced that it will launch the first full "virtual" clinical trial, using personal smart phones and wearable devices to track patients Patients participating in the clinical trial do not need to go to the clinical trial site in person for examination The clinical trial, called chief-ihf, aims to gather real-world evidence to support the company's new indications in the cardiovascular field of SGLT2 inhibitor canagliflozin (yaomingkant) Recently, exicure announced that it has signed a global cooperation agreement with Allergan The two companies will develop two new treatments for hair loss by using the unique 3D spherical nucleic acid platform technology of exicure (yaomingkant) Recently, Guizhou food and Drug Administration announced the information that Guizhou Guangzheng Pharmaceutical Co., Ltd produced Norfloxacin Capsules According to the decision on administrative penalty issued by Guizhou food and drug administration, the dissolution of two batches of Norfloxacin Capsules (batch No jae0910 and jae0824) produced by Guizhou Guangzheng was found to be inconsistent with the regulations by Zunyi food and Drug Inspection Institute A total of 79200 boxes of two batches of drugs have been produced At present, about 119 thousand boxes have been recalled and about 67200 boxes have been sold (pharmacy manager)